Treatment of squamous cell esophageal cancer with topotecan: An Eastern Cooperative Oncology Group Study (E2293)

Robert F. Asbury*, Stuart Lipsitz, David Graham, Carla I. Falkson, Luis Baez, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2 daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.

Original languageEnglish (US)
Pages (from-to)45-46
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume23
Issue number1
DOIs
StatePublished - Feb 1 2000

Fingerprint

Topotecan
Squamous Cell Neoplasms
Esophageal Neoplasms
Esophagus
Squamous Cell Carcinoma
Therapeutics
Vomiting

Keywords

  • Esophageal cancer
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Asbury, Robert F. ; Lipsitz, Stuart ; Graham, David ; Falkson, Carla I. ; Baez, Luis ; Benson, Al B. / Treatment of squamous cell esophageal cancer with topotecan : An Eastern Cooperative Oncology Group Study (E2293). In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2000 ; Vol. 23, No. 1. pp. 45-46.
@article{8449a3f8f733402297fab2beaf027ace,
title = "Treatment of squamous cell esophageal cancer with topotecan: An Eastern Cooperative Oncology Group Study (E2293)",
abstract = "Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2 daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.",
keywords = "Esophageal cancer, Topotecan",
author = "Asbury, {Robert F.} and Stuart Lipsitz and David Graham and Falkson, {Carla I.} and Luis Baez and Benson, {Al B.}",
year = "2000",
month = "2",
day = "1",
doi = "10.1097/00000421-200002000-00013",
language = "English (US)",
volume = "23",
pages = "45--46",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Treatment of squamous cell esophageal cancer with topotecan : An Eastern Cooperative Oncology Group Study (E2293). / Asbury, Robert F.; Lipsitz, Stuart; Graham, David; Falkson, Carla I.; Baez, Luis; Benson, Al B.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 23, No. 1, 01.02.2000, p. 45-46.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of squamous cell esophageal cancer with topotecan

T2 - An Eastern Cooperative Oncology Group Study (E2293)

AU - Asbury, Robert F.

AU - Lipsitz, Stuart

AU - Graham, David

AU - Falkson, Carla I.

AU - Baez, Luis

AU - Benson, Al B.

PY - 2000/2/1

Y1 - 2000/2/1

N2 - Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2 daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.

AB - Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2 daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.

KW - Esophageal cancer

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0034125908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034125908&partnerID=8YFLogxK

U2 - 10.1097/00000421-200002000-00013

DO - 10.1097/00000421-200002000-00013

M3 - Article

C2 - 10683076

AN - SCOPUS:0034125908

VL - 23

SP - 45

EP - 46

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -